MicroRNA-320 regulates the radiosensitivity of cervical cancer cells C33AR by targeting β-catenin

CHUN-XU YANG1, SHI-MIN ZHANG1, JIE LI1, BO YANG1, WEN QIYANG1, ZI-JIE MEI1, JING CHEN1, JING DAI1,2, SU KE1,2, FU-XIANG ZHOU1,2, YUN-FENG ZHOU1,2 and CONG-HUA XIE1,2

1Department of Radiation and Medical Oncology, Zhongnan Hospital; 2Department of Radio-Chemotherapy, Wuhan University, Wuhan, Hubei 430071; 3Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China

Received May 19, 2015; Accepted September 30, 2016

DOI: 10.3892/ol.2016.5340

Abstract. Cervical cancer is the second most common malignancy in women worldwide and always has recurrence owing to radioresistance. MicroRNA (miRNA or miR) has been identified to relate to the sensitivity of cancer radiotherapy. Here, we investigated the potential of miRNA-320 as a biomarker for radiosensitivity by targeting β-catenin in cervical cancer. A radioresistant cervical cancer cell line, C33AR, was established, and the radioresistance of C33AR cells was confirmed by a colony-formation assay. The expression of miRNA-320 was detected by reverse transcription-quantitative polymerase chain reaction, and compared between C33A and C33AR. β-catenin, the target of miRNA-320, was determined at the protein level by western blotting after transfecting the inhibitor of miRNA-320. The expression of miRNA-320 was markedly decreased in C33AR cells, which appeared to be more radioresistant, compared with its parental cell line C33A. Target prediction suggested that miRNA-320 negatively regulated the expression of β-catenin. Knockdown of β-catenin increased C33AR radiosensitivity, which revealed that the inhibition of β-catenin could rescue the miRNA-320-mediated cell radiosensitivity. On the other hand, overexpressing miRNA-320 increased C33AR radiosensitivity. In conclusion, miRNA-320 regulated the radiosensitivity of C33AR cells by targeting β-catenin. This finding provides evidence that miRNA-320 may be a potential biomarker of radiosensitivity in cervical cancer.

Introduction

Cervical cancer, the second most common malignancy in women worldwide, is often diagnosed at a local and advanced stage (1). Radiotherapy is one of the most important treatments (1). However, radioresistance (inherent and acquired) often circumvents the efficacy of radiotherapy (2). Many patients have tumour recurrence due to radiotherapeutic resistance (2). However, the mechanisms of radioresistance are poorly understood.

MicroRNAs (miRNAs or miRs) are a class of non-coding RNAs, ~20-22-nucleotides long, which negatively regulate the expression of many cancer-related genes by binding to 3’-untranslated regions (UTRs) (3-5). Considerable evidence suggests that miRNAs are associated with multiple processes, including the tumorigenesis, proliferation and migration of many types of cancer (6-9). For example, miRNA-610 downregulated vasodilator-stimulated phosphoprotein to influence the invasion and migration of gastric cancer cells (10), and miRNA-144 promoted cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of phosphatase and tensin homolog (11). Growing evidence suggests that some miRNAs are related to radioresistance, such as miRNA-31, miRNA-181, miRNA-324-3p and miRNA-214 (12-15). However, the functions of miRNAs in radioresistance are still largely unknown. In this study, X-rays induced the expression of miRNA-320 in the radioresistant cervix cancer subline C33AR. Furthermore, target prediction suggested that miRNA-320 influences cervical cancer radiosensitivity by targeting β-catenin. The activation of β-catenin plays a crucial role in human cancers through the canonical Wnt/β-catenin signaling pathway, and the expression of β-catenin in cervical carcinoma causes a malignant phenotype (16). Our findings therefore suggest that a decrease in the expression of miRNA-320 promotes radioresistance in the C33AR cervical cancer cell line by permitting β-catenin expression.

Materials and methods

Cell culture and transfection. The human cervical cell line C33A was obtained from the Shanghai Life Science
Establishing a radioresistant cervical cancer cell line. Cells were cultured to 80% confluence and then subjected to irradiation. Irradiation parameters were set as follows: Quality, 6 MV/X-rays; dose rate, 2 Gy/min; field, 35x35 cm; and 2 Gy each time, using a linear accelerator. Cells were kept at room temperature for ≤30 min during irradiation. One set of flasks was not irradiated and treated as wild type. After 24 h of incubation, the medium in each flask was exchanged for fresh medium to remove detached cells. Cells resistant to radiation were cultured in the same medium, which was exchanged for fresh medium every 2 days thereafter. To generate stable radioresistant clones, all the clones after 60 Gy radiation were expanded for >6 months without radiation to confirm the radioresistant phenotype before studies were undertaken. Two clones from C33A cells were established. The parental cells of wild-type stable clones were generated under the same conditions without irradiation.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and analysis. Total RNA was extracted from cell lines using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. For the detection of miRNAs, RNA was reverse transcribed using a specific RT primer for U6 and miRNA-320 (Guangzhou RiboBio Co., Ltd.) according to the protocol of the manufacturer. qPCR was carried out with SYBR Green I Mix (Takara RiboBio Co., Ltd., Dalian, China) in a 20-µl reaction volume (12.5 µl SYBR Green I Mix, 0.5 µl ROX reference dye II, 200 mM forward and reverse primer, 2 µl complementary DNA template and 8 µl double-distilled H2O) on the iCycler iQ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using the following protocol: 95°C for 20 s, followed by 40 cycles of 95°C for 10 s, 60°C for 20 s and 70°C for 10 s. The primers for miR-212/320/132/15a/16 for RT-qPCR were designed and synthesized by Guangzhou RiboBio Co., Ltd. The sequences for the remaining primers were as follows: β-catenin forward, 5'-GAAACGGCCTTTCTAGTGGAC-3' and reverse, 5'-CTGGCCCATATCCACCAAGAGT-3'; c-MYC forward, 5'-GGGTATGGAAACACCAGACG-3' and reverse, 5'-CCTTCTTCTGCCGCGTAAATA-3'; cyclin D1 forward, 5'-GAGGAAACGAAGTGCAGGAGG-3' and reverse, 5'-GGATGGAGGTTCGATCGAT-3'; and GAPDH forward, 5'-TGGAGAACCTCAGTACACA-3' and reverse, 5'-TTACGCTTACAGGATACCT-3'. Δ quantification cycle (Cq) was calculated by subtracting the Cq of U6 from the Cq of miRNA-320. ΔΔCq was then calculated by subtracting the ΔCq of the control from the ΔCq of the treatment group. The fold-change of miRNA expression was calculated by the equation 2^ΔΔCq (10).

Flow cytometric analysis of cell cycle distribution. Cells were harvested and washed with cold PBS three times, fixed with 70% ethanol at 4°C for 24 h, washed again three times with cold PBS and then stained with 50 mg/ml propidium iodide for 0.5 h at 37°C (Beyotime Institute of Biotechnology, Haimen, China). DNA content was analyzed on the Cytomics FC 500 (Beckman Coulter, Inc., Brea, CA, USA).

 Colony-formation assay. Cells in an exponential growth phase were plated into a 6-well plate at 100, 200, 400, 800, 1,000 and 2,000 cells per well, and then irradiated with 0, 2, 4, 6, 8 and 10 Gy. Cells were then incubated at 37°C in 5% CO2, 95% air for 9-12 days. When most cell clones had reached >50 cells, they were stained with 0.5% (w/v) crystal violet (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). The number of clones in the radioresistant group was compared with that in the wild-type group. The survival curves were obtained and analyzed with GraphPad Prism 4 statistical software (GraphPad Software, Inc., La Jolla, CA, USA). Three independent experiments were performed.

Cell proliferation assay. Cell proliferation was assessed using the WST-1 Cell Proliferation Reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), according to the manufacturer’s protocol. The C33AR cells were plated into a 96-well cell culture plate at 2,000 cells/well and then incubated at 37°C overnight to allow settling. Then, they were transfected with miRNA-320 agomir and negative control, and treated with 4 Gy X-ray radiation. Subsequently, 10 µl of WST-1 reagent was added in each well and incubated for 2 h at 37°C. Absorbance was subsequently determined at a wavelength of 450 nm (for measurements) and 650 nm (as reference) by a microplate reader (EnSpire; PerkinElmer, Inc., Waltham, MA, USA). Cell proliferation was calculated by subtracting the absorbance values of the samples from that of the medium alone (background level). The relative cell proliferation was normalized to that of the control group.
oligonucleotides, were synthesized by Shanghai GenePharma Co., Ltd. A negative control siRNA (Shanghai GenePharma Co., Ltd.) was used as a control siRNA. siRNA transfection was performed using Lipofectamine 2000 as indicated in the manufacturer's instructions. Briefly, subconfluent C33AR cells were plated in 6-well plates in regular growth medium. The next day, they were transfected with either 100 nM control siRNA or the β-catenin siRNAs for 6 h, followed by recovery in serum-containing medium. After 48 h of siRNAs transfection, the cells were harvested for protein isolation analysis.

Western blotting. Cells were washed with PBS and lysed in radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM sodium fluoride, 2 mM Na3VO4, 1 mM EDTA, 1 mM EGTA and a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Cell lysates were quantified for protein content by the bicinchoninic acid (BCA) method using a BCA kit (Bio-Rad Laboratories, Inc.). Then, 40 µg of protein was resolved in 12% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). Membranes were blocked in 5% bovine serum albumin (Beyotime Institute of Biotechnology) in TBS with Tween-20 (TBST) for 2 h, and then probed with primary antibodies against β-catenin (ab22656; Abcam, Cambridge, MA, USA), cyclin D1 (ab134175; Abcam), c-MYC (ab32072; Abcam) and GAPDH (KM1002T; Sunge Biotech Co., Ltd., Tianjin, China) at a 1:1,000 dilution at 4°C overnight, washed extensively with TBST three times, and incubated with secondary antibodies conjugated with horseradish peroxidase (Pierce; Thermo Fisher Scientific, Inc.) at room temperature for 2 h at a 1:5,000 dilution. Immunoreactive protein was examined using an enhanced chemiluminescence kit (Beyotime Institute of Biotechnology).

Statistical analysis. The results of the quantitative data in this study are expressed as the mean ± standard deviation. The Student's t-test was used to evaluate the significant difference between two groups of data in all pertinent experiments with the statistical package SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 (using a two-tailed paired t-test) was considered to indicate a statistically significant difference between two groups of data.

Results

Establishing and validating radioresistant C33AR cells. To generate a radioresistant cell line, C33A cells in exponential growth phase were exposed to X-rays at a dose of 2 Gy and a dose rate of 2 Gy/min. An interval of 1 to 3 weeks between each ionizing radiation (IR) allowed the surviving cells to regenerate. The whole process of IR and culture lasted for ~1 year, and the surviving cell line was termed C33AR. To verify phenotypes, C33AR cells were irradiated and examined by the colony-formation assay. Compared with C33A, C33AR showed no change in foci formation when IR was absent, but gained more foci and higher survival fractions when exposed to IR (Fig. 1A), establishing C33AR as a stable radioresistant cell line. Next, flow cytometry was used to evaluate alterations in the cell cycle (Fig. 1B and C). After irradiation, C33AR cells in the G1 and S phases significantly increased. Conversely, the proportion of C33AR in the G2/M phase decreased.

Differential expression of miRNAs and β-catenin in radioresistant cells. The differential miRNA expression profile between C33AR cells and their parental C33A cells was determined using RT-qPCR (Fig. 2A). The expression of miRNA-320 in C33AR cells was significantly lower than that in C33A cells. Several differentially expressed miRNAs in this profile were previously reported to have a role in tumorigenesis, including the development of radioresistance (17,18). These results indicated that differentially expressed miRNAs may contribute to the acquisition of radioresistance in cervical cancer. The expression of miRNA-320 was significantly changed in cervical cancer cells after radiation. In addition, β-catenin was highly expressed in C33AR cells compared with C33A cells at the protein level but not at the messenger RNA level (Fig. 2B and C).

miRNA-320 influences the sensitivity of C33AR and parental cells to irradiation. Based on the differential expression of miRNA-320 between C33AR and its parental C33A cells, the potential role of miRNA-320 in cervical cancer radiobiology was examined by overexpressing or repressing miRNA-320 using synthetic miRNA-320 agomir/antiagomir in C33AR and C33A cells, respectively. The expression of miRNA-320 was tested by RT-qPCR (Fig. 3A and B). Following miRNA-320 overexpression, the survival rate of C33AR cells decreased compared with that of C33AR cells transfected with negative control vector 10 days after IR stimulation (Fig. 3C). These results revealed that overexpression of miRNA-320 significantly increases the sensitivity of C33AR cells to irradiation. The expression of miRNA-320 in C33A cells was inhibited by being transfected with antiagomir, and caused a decrease in radiosensitivity (Fig. 3D). In the proliferation assay, C33AR cells were transfected with miRNA-320 agomir and negative control, and exposed to IR with 4 Gy x-rays, and their cell growth was monitored by counting the cell numbers (Fig. 3E). Increased expression of miRNA-320 promoted cell death in the experimental group with 4 Gy IR exposure in the long-term cell culture compared with the negative control.

Decrease in miRNA-320 induces the radioresistance of cervical cancer cells by targeting β-catenin expression. Hsieh et al have reported that miRNA-320 inhibits endogenous β-catenin expression and nuclear localization in prostate cancer (19). When β-catenin translocates to the nucleus, it activates the transcription of Wnt/β-catenin target genes, such as c-MYC and cyclin D1 (20). Therefore, to further explore the mechanism by which miRNA-320 influences cell radiosensitivity, the expression of β-catenin, c-MYC and cyclin D1 was examined by RT-qPCR and western blotting after transfecting C33AR cells with miRNA-320 agomir (Fig. 4A, B and D). Upon transfection with miRNA-320 antiagomir in C33A cells, the expression of β-catenin increased at the protein level (Fig. 4C). To confirm that miRNA-320 modulates the radiobiological behavior of cervical cancer cells by repressing β-catenin expression, rescue experiments were performed. First, β-catenin expression was inhibited using siRNAs (Fig. 4E) and then, the knockdown of β-catenin
increased C33AR radiosensitivity (Fig. 4F). The inhibition of β-catenin rescued miRNA-320-mediated cell radioresistance. These results indicated that a decrease in miRNA-320 inhibits cervical cancer cell radiosensitivity in vitro by negatively regulating β-catenin expression and Wnt/β-catenin signaling activity.
Radiotherapy is the main treatment for cervical cancer, especially at an early stage of the disease. However, many patients are not sufficiently radiosensitive and relapse soon after radiotherapy (1). The tumor radiation response is thus a major factor for the effect (and closely related to) tumor radiosensitivity. Numerous biological processes participate in the regulation of tumor radiation response, including DNA damage response and repair, cell cycle checkpoint, apoptosis control, and metabolism (21).

Although some achievements have been made in previous studies (22,23), the exact molecular mechanisms underlying radioresistance remain to be elucidated. In this study, a radioresistant cervical cancer cell line was identified using the clonogenic assay. Biological analyses revealed an increased percentage of G1-phase cells in the C33AR cell line compared with the parental cell line, suggesting its radioresistance, since it is generally accepted that cells are usually most sensitive to radiation in the late G2/M phase and most resistant to radiation in the mid-to-late S and early G1 phases (26).

The RT-qPCR results indicated that miRNA-320 was significantly decreased in the C33AR cell line. The in vitro functional analysis in our study demonstrated that a decrease in miRNA-320 confers radioresistance to the C33AR cell line, and that miRNA-320 overexpression induces increased radiosensitivity in C33AR cells. This alteration suggests that the differential expression of some miRNAs may be important for surviving the cytotoxic effects of radiation, thus supporting previous results demonstrated in other cancer types (27,28).

miRNA-320 is located on chromosome 8p21.3, a region frequently reported to undergo a loss of heterozygosity during the progression of prostate cancer (29). Altered miRNA-320 expression has also been linked to a defect in post-transcriptional processing and chromosomal...
deletions (29). The attenuation of miRNA-320 expression has also been demonstrated to be important for the initiation (30) and progression (31) of a number of cellular processes. The downregulation of miRNA-320 and the following radiosistant effect in C33AR cells support a critical role for this miRNA in modulating the cellular response to radiation. This is supported not only by the downregulation of miRNA-320 in our model but also in the larynx squamous carcinoma acquired radioresistant cell line Hep2R (32) in a previous study. However, the overexpression of miRNA-320 in the C33A cell line did not enhance radiosensitivity (data not shown). This may be explained by a plateau effect, given the relatively high basal expression of miRNA-320 in these cells, or it may suggest that the modulatory effect of miRNA-320 on the radiosensitivity of C33AR cells may depend on other molecular genetic changes that occurred during the generation of this radiosistant subline.

Radiation can induce different alterations in various oncogenes or cancer suppressor genes, including P53, Bcl-2-associated X protein, P21 and DNA-dependent protein kinase (33-35). Therefore, bioinformatic algorithms, including PicTar (picTar.bio.nyu.edu/), MicroRNA.org (www.microrna.org/microrna/home.do) and Targetscan (www.targetscan.org/), were used to determine that β-catenin, a well-known oncogene (36), is a potential target with the highest predictive value for miRNA-320. In addition, a previous study confirmed it as a target of miRNA-320 (19). The study, performed in prostate cancer cells, demonstrated that miRNA-320 influences stem cell-like characteristics by directly downregulating the Wnt/β-catenin signaling pathway (19). In the present study, miRNA-320 was identified as a critical contributor to radioresistance by directly targeting β-catenin in cervical cancer. Previous studies have demonstrated that the activation of the Wnt signaling pathway is a key radioprotective mechanism in irradiated cancer cells (37-40). Woodward et al reported that Wnt and β-catenin signaling may contribute to the radioresistance of breast cancer stem cells (41), and Watson et al reported that cells with silenced β-catenin are more sensitive to radiation compared with the parental cell line (42). The present report is the first to demonstrate an association between miRNA-320 downregulation and radioresistance through a negative

Figure 4. Decrease in miRNA-320 induces the radioresistance of cervical cancer cells by targeting β-catenin expression. Determination of β-catenin as a target of miRNA-320 and effect of β-catenin on the radiosensitivity of cervical cancer cells. (A) The mRNA expression of β-catenin, c-MYC and cyclin D1 was decreased after transfection with miRNA-320 agomir. (B) Decreased expression of miRNA-320 facilitates the expression of β-catenin. (C) Increased expression of miRNA-320 inhibits the expression of β-catenin. (D) The protein level of β-catenin, c-MYC and cyclin D1 was decreased after transfection with miRNA-320 agomir. (E) siRNA-mediated inhibition of β-catenin in C33AR cells. (F) β-catenin inhibition rescues miRNA-320-mediated radioresistance of C33AR in vitro. C33AR cells were transfected with si-3 and si-NC, and the survival fractions were determined. The results shown (mean ± standard deviation) are representative of three independent experiments ("P<0.05). miRNA, microRNA; NC, negative control; si/siRNA, small interfering RNA; mRNA, messenger RNA.
regulation of β-catenin. Although the colony-formation assay confirmed that the differential expression of miRNA-320 and the inverse expression of β-catenin are related to radioresistance, it remains unclear how the miRNA-320/β-catenin signaling pathway participates in establishing radioresistance in cervical cancer. Further work is required to elucidate these factors and to assess their importance in the radiation response of cervical cancer.

As traditional radiotherapy may result in the potential radioresistance of cervical cancer, the classical schedule requires a radiosensitive drug regimen to enhance its curative effect. The roles of miRNAs in the regulation of tumor radiosensitivity suggest that miRNAs will be a promising target for clinical diagnosis and treatment. In addition, the potential improvement of radiotherapeutic effects through activating or inhibiting the expression of certain miRNAs and downstream target genes is extremely promising. A thorough understanding of tumor radiosensitivity and the regulatory mechanisms of miRNAs will bring new hope to more cancer patients.

Acknowledgements

We thank the support provided by the National Natural Science Foundation of China (Beijing, China; grant nos. 81071908 and 81272996) and the Fundamental Research Funds for the Central Universities (Hubei, China; grant no. 2042014).

References

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Waggoner SE: Cervical cancer. Lancet 361: 2217-2225, 2003.
3. Bernstein E, Caudy AA, Hammond SM and Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 406: 363-366, 2000.
4. Sevignani C, Calin GA, Siracusa LD and Croce CM: Mammalian microRNAs: A small world for fine-tuning gene expression. Mamm Genome 17: 189-202, 2006.
5. Zhang B, Wang Q and Pan X: MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 210: 279-299, 2007.
6. Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell 148: 1172-1187, 2012.
7. Nikitina EG, Urazova LN and Stegny VN: MicroRNAs and human cancer. Exp Oncol 34: 2-8, 2012.
8. Xie H, Zhao Y, Caramuta S, Larsson C and Liu WO: miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One 7: e46999, 2012.
9. Aigner A: MicroRNAs (miRNAs) in cancer invasion and metastasis: Therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl) 89: 445-457, 2011.
10. Wang J, Zhang J, Wu J, Luo D, Su K, Shi W, Liu J, Tian Y and Wei L: MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein. Eur J Cancer 48: 1904-1913, 2012.
11. Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY and Fu L: MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 34: 454-463, 2013.
12. Lynnam-Leonno N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP and Maher SG: MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl) 90: 1449-1458, 2012.
13. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P and Hu W: MicroRNA-381a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 23: 997-1003, 2010.
14. Li G, Liu Y, Su Z, Ren S, Zhu G, Tian Y and Qiu Y: MicroRNA-324-3p regulates nasopharyngeal carcinoma radio-resistance by directly targeting WNT2B. Eur J Cancer 49: 2750-2756, 2013.
15. Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegheh A, Viktorsson K and Zhivotovsky B: miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 107: 1361-1373, 2012.
16. Saito M, Yamaura A, Yokoyama Y, Watanabe M, Wan X, Takahashi Y, Mori Y, Takami T, Shimokawa K and Tamaya T: Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol 82: 450-455, 2001.
17. Zhao Z, Su T, Ye J, Yang C, Zhang S and Xie C: The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints. Radiat Res 183: 196-207, 2015.
18. Jiang X, Chen X, Chen L, Ma Y, Zhou L, Qi P, Liu Y, Zhang S, Luo J and Zhou X: Upregulation of the miR-212/132 cluster suppresses proliferation of human lung cancer cells. Oncol Rep 33: 705-712, 2015.
19. Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-239 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 34: 530-538, 2013.
20. Valenta T, Haussmann G and Basler K: The many faces and functions of β-catenin. Embo J 31: 2714-2736, 2012.
21. Zhao L, Lu X and Cao Y: MicroRNA and signal transduction pathways in tumor radiation response. Cell Signal 25: 1625-1634, 2013.
22. López J, Poitevin A, Mendoza-Martínez V, Pérez-Plasencia C and García-Carrancá A: Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 12: 48, 2012.
23. Ke G, Liang L, Yang JM, Huang X, Pan D, Huang S, Zhao Y, Zha R, He X and Wu X: MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene 32: 3019-3027, 2013.
24. Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia WH, Liu M, Li X and Tang H: MicroRNA-19a and -19b regulate cervical cell proliferation and invasion by targeting CUL5. Cancer Lett 322: 148-158, 2012.
25. Tang T, Wong HK, Gu W, Yu MY, To KE, Wang CC, Wong YF, Cheung TH, Chung TK and Choy KW: MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 129: 199-208, 2013.
26. Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 592-96, 2004.
27. Shinbata M, Shinozuka K, Saito K, Fujishini K, Kasamatsu A, Ogawara K, Uzawa K, Ito H, Takiguchi Y and Tanzawa H: MicroRNA-125b regulates proliferation and radiosensitivity of oral squamous cervical carcinoma. Br J Cancer 108: 1817-1821, 2013.
28. John-Aryankalayil M, Palayoor ST, Makinde AE, Cerna D, Simone CB II, Falduto MT, Magnuson SR and Coleman CN: Fractionated radiation alters oncomir and tumor suppressor microRNAs in human prostate cancer cells. Radiat Res 178: 105-117, 2012.
29. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC and Troncoso P: Homozygous deletions at 8q22 and 9p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11: 2181-2186, 1993.
30. Kim BM and Choi MY: Non-canonical microRNAs miR-320 and miR-702 promote proliferation in Dgcr8-deficient embryonic stem cells. Biochem Biophys Res Commun 426: 183-189, 2012.
31. Ren XP, Wu J, Wang X, Sarton MA, Qian J, Jones K, Nicolau P, Pritchard TJ and Fan GC: MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119: 2357-2366, 2009.
32. Zhou FX, Xiong J, Luo ZG, Dai J, Yu HJ, Liao ZK, Lei H, Xie CH and Zhou YF: cDNA expression analysis of a human radiosensitive-radioresistant cell line model identifies telomere function as a hallmark of radioresistance. Radiat Res 174: 350-357, 2010.
33. Zhang M, Atkinson RL and Rosen JM: Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 107: 3522-3527, 2010.
34. Theys J, Yahyanejad S, Habets R, Span P, Dubois L, Paesmans K, Kattenfeld B, Cleutjens J, Groot AJ, Schuurhuis OC, et al: High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiother Oncol 108: 440-445, 2013.

35. Huerta S, Gao X, Dineen S, Kapur P, Saha D and Meyer J: Role of p53, Bax, p21 and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery 154: 143-151, 2013.

36. Kim KH, Seol HJ, Kim EH, Rheey J, Jin JH, Lee Y, Joo KM, Lee J and Nam DH: Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol 15: 161-171, 2013.

37. Orford K, Orford CC and Byers SW: Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, apoptosis, and radiation-induced cell cycle arrest. J Cell Biol 146: 855-868, 1999.

38. Nakashima M, Melmanov S, Matsufuji R, Hayashida M, Fukuda E, Naito S, Matsuu M, Shichijo K, Kondo H, Ito M, et al: Altered expression of beta-catenin during radiation-induced colonic carcinogenesis. Pathol Res Pract 198: 717-724, 2002.

39. Rodningen OK, Overgaard J, Alsner J, Hastie T and Børresen-Dale AL: Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. Radiother Oncol 77: 231-240, 2005.

40. Gassler N, Herr I, Keith M, Autschbach F, Schmitz-Winnenthal H, Ulrich A, Otto HF, Kartenbeck J and Z'graggen K: Wnt-signaling and apoptosis after neoadjuvant short-term radiotherapy for rectal cancer. Int J Oncol 25: 1543-1549, 2004.

41. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104: 618-623, 2007.

42. Watson RL, Spalding AC, Zieske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, et al: GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia 12: 357-365, 2010.